onc Videos

Videos

Videos

What Is the Optimal Combination for Patients With Multiple Myeloma in Early Relapse?

02/16/2023

Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Faith E. Davies, MD, provides an...

02/16/2023

Oncology

Videos

What Every Doctor Should Know About Clonal Hematopoiesis

02/15/2023

Pinkal Desai, MD, provides the latest updates on clonal hematopoiesis, highlighting what doctors should know about these aging-associated mutations.

Pinkal Desai, MD, provides the...

02/15/2023

Oncology

Sebastian Stintzing, MD, Charité — Berlin University of Medicine

Videos

Initial Cycle of Chemotherapy Does Not Influence Efficacy of First-Line FOLFIRI Plus Cetuximab for RAS Wild-Type Colorectal Cancer

02/08/2023

Sebastian Stintzing, MD, shares results from the phase 3 FIRE-4 trial showing the administration of an initial cycle of chemotherapy had no effect on the efficacy of first-line FOLFIRI plus cetuximab therapy for patients with RAS wild-type...

Sebastian Stintzing, MD, shares...

02/08/2023

Oncology

Zev Wainberg, MD, University of California - Los Angeles

Videos

First-Line NALIRIFOX Conveys Survival Benefits for Metastatic Pancreatic Ductal Adenocarcinoma

02/07/2023

Zev Wainberg, MD, reviews results from the NAPOLI-3 study, the first study since 2010 to show an overall survival advantage in pancreatic cancer.

Zev Wainberg, MD, reviews...

02/07/2023

Oncology

Videos

Expedited FDA Approval of Teclistamab for Relapsed/Refractory Multiple Myeloma

02/05/2023

Ajai Chari, MD, provides insight into the FDA approval of teclistamab for relapsed/refractory multiple myeloma and background on the data that led to this approval.

Ajai Chari, MD, provides insight...

02/05/2023

Oncology

Videos

Teclistamab Combined With Subcutaneous Daratumumab and Lenalidomide in Patients With Multiple Myeloma

02/05/2023

Emma Searle, MD, discusses treatment with teclistamab combined with subcutaneous daratumumab and lenalidomide for patients with multiple myeloma.

Emma Searle, MD, discusses...

02/05/2023

Oncology

Videos

Daratumumab Plus Lenalidomide and Dexamethasone Demonstrates Survival Benefits for Transplant-Ineligible Patients With Newly Diagnosed MM

02/05/2023

Shaji K. Kumar, MD, discusses the PFS and OS benefit seen with daratumumab added to lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in transplant-ineligible patients with newly diagnosed multiple myeloma.

Shaji K. Kumar, MD, discusses...

02/05/2023

Oncology

Videos

Mitapivat Improves Markers of Erythropoietic Activity in Adults With Alpha- or Beta-Non-Transfusion-Dependent Thalassemia

02/05/2023

Kevin H.M. Kuo, MD, discusses the use of mitapivat to improve erythropoiesis in patients with alpha- or beta-non-transfusion-dependent thalassemia.

Kevin H.M. Kuo, MD, discusses...

02/05/2023

Oncology

Stacey Cohen, MD, Fred Hutchinson Cancer Center

Videos

What is the Optimal Timing to Test for Circulating Tumor DNA to Detect MRD in Colorectal Cancer?

02/02/2023

Stacey Cohen, MD, reviews results from a study evaluating the optimal timing to test for circulating tumor DNA to detect MRD following surgery in patients with colorectal cancer.

Stacey Cohen, MD, reviews...

02/02/2023

Oncology

Videos

Tucatinib Plus Trastuzumab Receives FDA Approval for RAS Wild-Type, HER2-Positive Colorectal Cancer

02/02/2023

John Strickler, MD, shares insights on the FDA’s accelerated approval of tucatinib in combination with trastuzumab for patients with RAS wild-type, HER2-positive colorectal cancer.

John Strickler, MD, shares...

02/02/2023

Oncology

Recent News

News

Pembrolizumab Plus Gemcitabine-Platinum Doublet Chemotherapy Improves Survival Regardless of Platinum Agent for Urothelial Carcinoma

11/19/2024

Stephanie Holland ;

Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...

Subset analysis results from the...

11/19/2024

Oncology

News

Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/19/2024

Stephanie Holland ;

Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.

Results from the phase 3...

11/19/2024

Oncology

News

Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer

11/19/2024

Allison Casey ;

According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.

According to a phase 2 trial,...

11/19/2024

Oncology

News

Robotic Laparoscopy May Have Easier Recovery For Patients With Early-Stage, Low Risk Endometrial Cancer

11/19/2024

Allison Casey ;

According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.

According to a randomized...

11/19/2024

Oncology

News

UGN-102 Chemoablation as TURBT Alternative for Patients With Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer

11/19/2024

Stephanie Holland ;

According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...

According to results from the...

11/19/2024

Oncology

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology